PaloBiofarma
A company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
$31—46m (Dealroom.co estimates Feb 2024.)
Company register number B63998843
Mataró Catalonia (HQ)
Authorizing premium user...